LEXEO Therapeutics

Harnessing Genetic Medicine’s Potential in Cardiology

Fresh Off IPO: Following Lexeo’s IPO in November, the company showed ability to breakthrough during difficult market with investors and analysts identifying potential of technology followed up with a PIPE investment in March.
Varied Pipeline: Using AAV vectors, Lexeo is targeting the genetic causes of cardiac conditions like cardiac Friedreich ataxia and arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM). This is coupled with a pipeline of genetic CNS conditions, including APOE4-associated Alzheimer’s, for a well-rounded pipeline of genetic medicine programs.
Interim data from Lexeo’s lead SUNRISE-FA Phase 1/2 program of LX2006 in cardiac Friedreich ataxia anticipated in mid-2024.
Additional milestones in the second half of 2024:
- Interim data readout of Cohort 1 of the Phase 1/2 clinical trial of LX2020 in PKP2-ACM
- Interim data readout of the Phase 1/2 clinical trial of LX1001 in APOE4-associated Alzheimer’s
- Initiation of IND-enabling studies of LX2021 in Desmoplakin (DSP) cardiomyopathy